share_log

Baird Initiates Coverage On Bright Minds Biosciences With Outperform Rating, Announces Price Target of $75

Baird Initiates Coverage On Bright Minds Biosciences With Outperform Rating, Announces Price Target of $75

贝尔德对Bright Minds Biosciences启动覆盖,给予跑赢大盘评级,宣布目标价格为75美元。
Benzinga ·  11/26 05:21  · 评级/大行评级

Baird analyst Joel Beatty initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $75.

贝尔德分析师乔尔·比蒂以跑赢大盘的评级启动了对Bright Minds Biosciences(纳斯达克股票代码:DRUG)的报道,并宣布目标股价为75美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发